Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery

Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Observation is watching a patient's condition but not giving treatment until symptoms appear. It is not yet known whether giving gemcitabine hydrochloride together with oxaliplatin is more effective than observation in treating patients with biliary tract cancer that has been removed by surgery.

PURPOSE: This randomized phase III trial is studying giving gemcitabine hydrochloride together with oxaliplatin to see how well it works compared with observation in treating patients with biliary tract cancer that has been removed by surgery.

Study Overview

• Status: Completed
• Conditions: Liver Cancer; Gallbladder Cancer; Extrahepatic Bile Duct Cancer
• Intervention / Treatment: Procedure: adjuvant therapy; Drug: oxaliplatin; Drug: gemcitabine hydrochloride; Procedure: quality-of-life assessment; Other: clinical observation

Detailed Description

OBJECTIVES:

Primary

• Compare disease-free survival (DFS) of patients with resected biliary tract cancer treated with adjuvant gemcitabine hydrochloride and oxaliplatin versus clinical observation.
• Compare quality of life of these patients.

Secondary

• Compare overall survival of these patients.
• Determine the toxicity of the chemotherapy in these patients.
• Explore prognostic factors for DFS including resection result (R0 vs R1), location of primary tumor (intrahepatic vs extrahepatic vs gallbladder), evolution of CA19-9, and lymph node involvement (N0 vs N+ and Nx). (Exploratory)
• Study pathological factors in surgical specimens to identify main characteristics and phenotypic clinicoanatomical biliary tract cancers before therapy. (Exploratory)
• Identify nontumor-associated liver injury and factors that may facilitate the emergence of biliary tract cancers. (Exploratory)
• Identify signaling pathways that may predict response to therapy. (Exploratory)
• Determine the molecular characteristics to differentiate tumors according to their position in the biliary tract (extrahepatic bile duct, intrahepatic cholangiocarcinoma site [hilar], and peripheral cholangiocarcinoma vesicle site). (Exploratory)

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment repeats every 14 days for 12 courses.
• Arm II: Patients undergo clinical observation only every 4 weeks for 5 months. Quality of life is assessed at baseline, at 3 and 6 months, and then at all follow-up visits.

After completion of study therapy, patients are followed up at 6 months, every 3 months for 2 years, and then every 6 months for 3 years.

• Study Type: Interventional
• Enrollment (Actual): 190
• Phase: Phase 3

Contacts and Locations

Study Locations

• France
  • Amiens, France, 80054
    • Chu - Hopital Nord
  • Angers, France, 49933
    • Centre Paul Papin
  • Avignon, France, 84082
    • Institut Sainte Catherine
  • Bayonne, France, 64109
    • Centre Hospitalier de la Cote Basque
  • Besancon, France, 25030
    • Hôpital Jean Minjoz
  • Bobigny, France, 93009
    • Hôpital Avicenne
  • Brest, France, 29200
    • CHU Brest - Hopital Morvan
  • Caen, France, 14000
    • CHU Côte de Nacre
  • Clermont Ferrand, France, 63003
    • Chu Estaing
  • Clichy, France, 92118
    • Hopital Beaujon
  • Créteil, France, 94000
    • Hôpital Henri Mondor
  • Dijon, France, 21079
    • Hôpital Bocage
  • La Roche Sur Yon, France, 85925
    • CHD Vendee
  • Lyon, France, 69008
    • Centre Leon Berard
  • Lyon, France, 69437
    • Hopital Edouard Herriot
  • Lyon, France, 69373
    • Hopital Prive Jean Mermoz
  • Marseille, France, 13273
    • Institut Paoli Calmettes
  • Marseille, France, 13015
    • Hopital Nord
  • Marseille, France, 13008
    • Hopital Saint Joseph
  • Marseille, France, 13385
    • CHU Timone Adulte
  • Montpellier, France, 34295
    • Centre Hospitalier Saint Eloi
  • Nantes, France, 44805
    • Centre René Gauducheau
  • Orléans, France, 45067
    • Hopital La Source
  • Paris, France, 75012
    • Hôpital Saint Antoine
  • Paris, France, 75014
    • Institut Mutualiste Montsouris
  • Paris, France, 75908
    • Hôpital Européen Georges Pompidou
  • Paris, France, 75651
    • Hopital de La Pitie Salpetriere
  • Paris, France, 75475
    • CHU Saint Louis
  • Poitiers, France, 86021
    • Chu de Poitiers
  • Rennes, France, 35042
    • Centre Eugene Marquis
  • Rouen, France, 76031
    • CHU de Rouen - Hôpital Ch. Nicolle
  • Sainte-Etienne, France, 42255
    • CHU Sainte-Etienne - Hopital Nord
  • Strasbourg, France, 67065
    • Centre Paul Strauss
  • Strasbourg, France, 67098
    • Hôpital de Hautepierre / Hôpital Civil
  • Tours, France, 37044
    • Hôpital Trousseau
  • Vandouevre Les Nancy, France, 54511
    • Chu Brabois
  • Villejuif, France, 94800
    • Institut Gustave Roussy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 120 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

DISEASE CHARACTERISTICS:

• Histologically proven adenocarcinoma of the intrahepatic bile ducts, gallbladder, or extrahepatic bile ducts

  • Mixed forms of hepatocholangiocarcinomas included provided the cholangiocarcinoma is predominant
• Underwent surgical resection of the disease (R0 or R1) at least 4 weeks but no more than 13 weeks ago
• Nonmetastatic disease as assessed by abdominal MRI and chest x-ray
• No cancer of the pancreas or duodenum invading the bile duct and ampulla of Vater

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Hemoglobin ≥ 10 g/dL (transfusion allowed)
• ANC ≥ 1,500/mm³
• Platelet count ≥ 75,000/mm³
• Creatinine clearance > 40 mL/min
• Prothrombin time > 60% OR INR < 1.5 (without anticoagulant therapy)
• Transaminases ≤ 5 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2.5 times ULN
• Conjugated bilirubin ≤ 35 μmol/L (after biliary drainage, if necessary)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No contraindications to oxaliplatin and gemcitabine hydrochloride therapy
• Prior invasive cancer allowed provided it has been in complete remission for ≥ 5 years
• No other concurrent invasive cancer except adequately treated carcinoma in situ of the cervix or basal cell carcinoma
• No other severe, unresolved disease
• No mental illness
• No HIV positivity
• No grade 1 angina or symptomatic angina ≥ grade 2
• No sensitive peripheral neuropathy
• No uncontrolled diabetes
• No inability to undergo medical tests due to geographical, social, or psychological reasons
• No prisoners or patients under guardianship
• No Child B or C cirrhosis

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior neoadjuvant chemotherapy or radiotherapy
• No prior organ transplantation
• No concurrent participation in another clinical trial of an experimental agent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ARM A: Gemox 85; Adjuvant chemotherapy for six months with gemcitabine - oxaliplatin 85mg / m² ( GEMOX 85)	Procedure: adjuvant therapy; Drug: oxaliplatin; Drug: gemcitabine hydrochloride; Procedure: quality-of-life assessment
Other: ARM B: Observation until progression or death	Procedure: quality-of-life assessment; Other: clinical observation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Disease-free survival	up to 3 years
Quality of life	up to 3 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Overall survival	up to 3 years
Toxicity of adjuvant chemotherapy	up to 3 years

Collaborators and Investigators

• Sponsor: UNICANCER
• Investigators: Principal Investigator: Eveline Boucher, MD, Centre Eugene Marquis

Study record dates

Study Major Dates

• Study Start: July 1, 2009
• Primary Completion (Actual): June 1, 2016
• Study Completion (Actual): June 1, 2016

Study Registration Dates

• First Submitted: March 10, 2011
• First Submitted That Met QC Criteria: March 10, 2011
• First Posted (Estimate): March 11, 2011

Study Record Updates

• Last Update Posted (Estimate): January 25, 2017
• Last Update Submitted That Met QC Criteria: January 24, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Keywords: cholangiocarcinoma of the gallbladder; cholangiocarcinoma of the extrahepatic bile duct; adenocarcinoma of the gallbladder; adenocarcinoma of the extrahepatic bile duct; localized extrahepatic bile duct cancer; localized gallbladder cancer; liver and intrahepatic biliary tract cancer
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Gallbladder Diseases; Biliary Tract Diseases; Bile Duct Diseases; Biliary Tract Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Bile Duct Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Gemcitabine; Oxaliplatin
• Other Study ID Numbers: CDR0000696193; FRE-FNCLCC-ACCORD-18/0803; FRE-FNCLCC-PRODIGE-12; EUDRACT-2008-004560-39; EU-20982